pifithrin has been researched along with Osteogenic Sarcoma in 2 studies
pifithrin: a tetrahydrobenzothiazol; inhibitor of P53 that protects mice from the side effects of cancer therapy; structure in first source
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, X | 1 |
| Zhu, S | 1 |
| Lee, SY | 1 |
| Shin, SJ | 1 |
| Kim, HS | 1 |
2 other studies available for pifithrin and Osteogenic Sarcoma
| Article | Year |
|---|---|
Prognosis-related VDAC1 regulates the proliferation and apoptosis of osteosarcoma cells via the MAPK signaling pathway.
Topics: Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Humans; Osteosarcoma; Prognosis; Si | 2023 |
ERK1/2 activation mediated by the nutlin‑3‑induced mitochondrial translocation of p53.
Topics: Antioxidants; Apoptosis; Benzothiazoles; Butadienes; Cell Line, Tumor; Cyclic N-Oxides; Enzyme Activ | 2013 |